ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/24/201510:48:12Correction to Merck Hepatitis C Treatment Story Update
04/24/201510:26:22Merck: Hepatitis C Treatment Shows 95% Cure Rate -- Update
04/24/201510:02:02Illumina's Earnings Set Positive Tone for Biotech
04/24/201508:20:16Merck Says Experimental Hepatitis C Treatment Shows 95% Cure...
04/24/201507:57:21Merck Says Experimental Hepatitis C Treatment Shows 95% Cure...
04/24/201506:09:00Zulassungsrelevantes Phase-3-Studienprogramm C-EDGE von MSD zur...
04/24/201502:24:00Le programme d'essais pivot de phase III C-EDGE de MSD , qui...
04/24/201501:00:00Il programma registrativo di fase 3 C-EDGE di MSD per la valutazione...
04/24/201501:00:00Merckâs Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir S...
04/23/201514:59:00MSD gibt Ergebnisse einer Phase-2/3-Studie zu in der Erprobung...
04/23/201512:49:55Eli Lilly Results Top Expectations
04/23/201512:44:52Eli Lilly Results Top Expectations
04/23/201510:02:00MSD annuncia i risultati dello studio di fase 2/3 del trattamento...
04/23/201503:30:00Merck Announces Results from Phase 2/3 Study of Investigational...
04/23/201503:30:00MSD annonce les résultats de l'étude de phase 2/3 du traitement e...
04/22/201521:17:45Meet Pharma's Newest Movers and Shakers, Driving M&A
04/22/201520:12:06Meet Pharma's Newest Movers and Shakers, Driving M&A
04/22/201511:43:00Roche Revenue Lifted by Cancer Drugs -- 2nd Update
04/22/201508:11:02Is Immuno-Oncology the Best Area of Biotech to Invest in Right...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad